10 Sept - Asia Bio Day 2Wednesday, 10 September 2025 - SGT / Singapore

The state-owned trade and investment Agency NRW.Global Business is the partner for all companies when it comes to investment projects and settling in North Rhine-Westphalia, Germany's No. 1 investment location. NRW.Global Business furthermore conducts activities to support companies from NRW in international growth markets and in networking with international business partners. In close coordination with its partners, NRW.Global Business provides a variety of measures tailored to the companies' needs: It is responsible for the organisation of joint trade fair presentations abroad as well as the coordination and support of international trade delegations from North Rhine-Westphalia to foreign countries. Numerous other industry information and brokerage events offer companies additional assistance in setting up and expanding international business.

CK Life Sciences, a member of the CK Hutchison Group, is listed on the Hong Kong Stock Exchange. With an ambition of improving Health & Wellness, CK Life Sciences is engaged in healthcare R&D, with operating businesses in Nutraceuticals and Agricultural-related sectors providing steady revenue that enables our R&D sustainability.

CaSRevolution is a biotech company developing a first-in-class therapeutic approach for Alzheimer’s disease. Our innovation targets the Calcium Sensing Receptor (CaSR), a key trigger of the neurotoxic cascade initiated by Abeta oligomers. By blocking CaSR with proprietary Negative Allosteric Modulators, we aim to halt amyloid accumulation, tau hyperphosphorylation, and neuroinflammation, addressing Alzheimer’s at its root cause.

DotBio is an emerging biotech company based in Singapore and San Francisco, focused on the rapid development of next-generation antibody therapeutics for diseases with significant unmet need. DotBio’s platform integrates advances in computational biology and molecular engineering to efficiently generate high-quality antibodies against challenging targets, including both extracellular and intracellular targets involved in cancer and autoimmune disorders.

Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ), was jointly founded by CP Group, a Thai company and Jiangsu Nongken Group. NJCTTQ specializes in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, tumors supportive care, perioperative care, gastrointestinal disorders and contrast agents. We have more than 10 innovative programs, covering areas such as breast cancer, IgAN, PNH, acromegaly and etc for out-licensing. We also welcome opportunities for in-licensing projects. We embrace various models of cooperation

TaiMed Biologics is a publicly listed biotechnology company headquartered in Taipei, Taiwan, dedicated to developing and commercializing innovative biologics that address urgent unmet medical needs. Founded in 2007, TaiMed has built a global reputation as a pioneer in HIV monoclonal antibody therapeutics, with proven capabilities spanning discovery, clinical development, regulatory approval, and large-scale biologics manufacturing.

Matwings Technology is dedicated to move beyond directed evolution methods to design and engineer functionally optimized proteins with proprietary AI models and ultra-large curated dataset with in house functional labels.

Here, we will present our proprietary oral uricase with superior stability in simulated intestinal fluid (SIF). This preclinical stage candidate can lower the serum uric acid by more than 50% in UOX mouse model with much less kidney injuries compared to allopurinol treatment.

The Alluminox™ platform is an investigational platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is developing the Alluminox platform as a technology consisting of a drug, device, and other related components. The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding.

Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis’s lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA.

AdAlta (ASX: 1AD) is an Australian clinical stage biotechnology company addressing the need for effective cellular immunotherapies for the treatment of solid cancers. CAR-T cell therapies are transforming blood cancer outcomes and Asia/China is fast becoming the leading innovation hub for biotech innovation, especially in CAR-T. Barriers remain to bringing the promise of CAR-T to solid cancers and bringing Asian innovation to the world. AdAlta is solving these challenges by spinning out its ‘East to West’ cellular immunotherapy subsidiary, AdCella, to integrate Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients. AdCella in-licenses clinical stage, first in class solid cancer products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies in Australia, positioning each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization. AdAlta has also created two novel protein assets available for partnering: - AD-214 is a first in class fusion protein taking a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of lung an and two successful Phase I clinical studies, AD-214 is available for partnering. -WD-34 is a first in class protein that is the world's first antibody like molecule offering high potency inhibition of malarial parasite invasion with pan-strain efficacy. WD-34 has potential to transform malaria and babesiosis prophylaxis from daily oral medications to single shot seasonal prophylaxis.

At Tikva Allocell, our mission is to develop safe, effective, readily available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of ALLO EBVST and proprietary technologies that enhance the T cell's performance to treat cancer and autoimmune diseases.